保留乳房手术前单纯全乳大分割放疗的试点/II期试验
本II期试验纳入22例cT0-T2、N0、M0乳腺癌患者,在保留乳房手术前4至8周给予全乳大分割放疗25 Gy分5次。2级及以上毒性发生率为32%,3级毒性为9%,生活质量未见显著变化,64%患者达到RCB-0或RCB-I。作者认为该方案可行,毒性低且美容效果好,但需进一步研究。
要点
- 保留乳房手术前给予全乳放疗25 Gy分5次,2级及以上毒性发生率为32%,3级毒性为9%。
- 生活质量线性模拟自评和PROMIS评分较基线无显著变化(P=.21和P=.72)。
- 64%患者达到RCB-0或RCB-I,其中14%为病理完全缓解(RCB-0)。
核心结论
- 保留乳房手术前给予极度大分割全乳放疗是可行的方案。
- 该方案毒性发生率低且美容效果好。
- 作者认为需要进一步研究保留乳房手术前放疗这一方案。
研究设计与样本
- II期试验,2019年至2020年纳入22例cT0-T2、N0、M0乳腺癌患者。
- 患者接受全乳大分割放疗25 Gy分5次,于保留乳房手术前4至8周完成。
- 采用残余肿瘤负荷(RCB)进行病理评估,毒性按不良事件通用术语标准第4版评估。
主要发现
- 中位随访7.6个月(范围0.2-16.8)。
- 7例(32%)患者发生2级及以上毒性,2例(9%)发生3级毒性。
- 生活质量线性模拟自评和PROMIS评分较基线无显著变化(P=.21和P=.72)。
- 乳腺癌治疗结局量表各领域均无临床显著变化(≥1分)。
- 仅1例(5%)患者出现临床恶化,对应哈佛美容量表「一般」结局;病理评估14例(64%)为RCB-0或RCB-I,其中3例(14%)为病理完全缓解(RCB-0),8例(36%)为RCB-II;未观察到局部或远处复发。
关键数值与推荐
- 全乳大分割放疗剂量为25 Gy分5次,于保留乳房手术前4至8周给予。
- 2级及以上毒性发生率为32%(7/22),3级毒性发生率为9%(2/22)。
- RCB-0或RCB-I为64%(14/22),病理完全缓解(RCB-0)为14%(3/22),RCB-II为36%(8/22)。
临床怎么用
- 作者认为保留乳房手术前极度大分割全乳放疗是可行方案,毒性低且美容效果好。
- 作者认为需要进一步研究保留乳房手术前放疗这一方案。
局限性
- 中位随访仅7.6个月(范围0.2-16.8)。
- 作者认为需要进一步研究保留乳房手术前放疗这一方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our purpose was to report the results of a phase II trial of patients with breast cancer treated with hypofractionated whole breast radiation therapy (RT) before breast-conserving surgery (BCS). METHODS AND MATERIALS: Between 2019 and 2020, patients with cT0-T2, N0, M0 breast cancer were enrolled. Patients were treated with hypofractionated whole breast RT, 25 Gy in 5 fractions, 4 to 8 weeks before BCS. Pathologic assessment was performed using the residual cancer burden (RCB). Toxicities were assessed according to Common Terminology Criteria for Adverse Events (version 4). Quality of life was assessed with Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, The Breast Cancer Treatment Outcome Scale, Linear Analogue Self-Assessment, and Patient-Reported Outcomes Measurement Information System. RESULTS: Twenty-two patients were enrolled. Median follow-up was 7.6 months (range, 0.2-16.8). Seven (32%) and 2 (9%) patients experienced grade 2+ or 3 toxicities, respectively. Overall quality of life Linear Analogue Self-Assessment and Patient-Reported Outcomes Measurement Information System did not change significantly from baseline (P = .21 and P = .72, respectively). There was no clinically significant change (≥1 point) in any of The Breast Cancer Treatment Outcome Scale domains. Only 1 (5%) patient experienced a clinical deterioration that corresponded to a "fair" outcome on the Harvard Cosmesis Scale. At pathologic evaluation, 14 (64%) patients had RCB-0 or RCB-I, including 3 (14%) patients with a pathologic complete response (RCB-0). Eight patients (36%) had RCB-II. No local or distant recurrences have been observed. CONCLUSIONS: Extremely hypofractionated whole breast RT before BCS is a feasible approach. There were low rates of toxicities and good cosmesis. Further investigation into this approach with RT before BCS is warranted.
引用
- Thorpe CS, DeWees TA, Laughlin BS, et al. Pilot/Phase II Trial of Hypofractionated Radiation Therapy to the Whole Breast Alone Before Breast Conserving Surgery. Adv Radiat Oncol. 2022. PMID: 36483068. doi:10.1016/j.adro.2022.101111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。